Abstract:Flurbiprofen axetil is commonly utilized in clinical practice as one of the nonsteroidal anti‐inflammatory drugs (NSAIDs) and is included in multimodal analgesia regimens postbreast cancer surgery. Numerous NSAIDs have been studied for their potential to both promote and inhibit cancer. Given the variability in their effects on tumors, further investigation into the specific role of flurbiprofen axetil is warranted. Therefore, the primary objective of this study was to assess the impact of flurbiprofen axetil on basal‐like breast cancer (BLBC) metastasis and elucidate the underlying molecular mechanisms involved. The BLBC metastasis mouse model was established by caudal vein injection of tumor cells. The lung metastasis of breast cancer in mice and the effect of flurbiprofen axetil were assessed by in vivo bioluminescence imaging, hematoxylin and eosin staining and immunohistochemistry. In vitro, the results of flurbiprofen axetil on the proliferation, migration, and invasion of MDA‐MB‐231 human breast cancer cells and BT‐549 human breast cancer cells were assessed by colony formation assay and transwell assay. The effects of flurbiprofen axetil on several tumor metastasis‐related signaling pathway proteins were examined by western blot, and the reversal extent of the flurbiprofen axetil effect by Ro 67‐7476 (ERK phosphorylation agonist) was detected by transwell assay. The results showed that flurbiprofen axetil significantly inhibited BLBC lung metastasis in mice. Flurbiprofen axetil similarly inhibited breast cancer cell migration and invasion in vitro but did not affect their proliferation. Mechanistic investigations have revealed that flurbiprofen axetil exerts a noteworthy inhibitory influence on the MEK/ERK pathway while exhibiting no significant alteration in the expression of other pathway proteins intricately associated with epithelial–mesenchymal transition. In conclusion, the inhibitory effect of flurbiprofen axetil on BLBC metastasis is characterized by its selectivity in targeting the MEK/ERK signaling pathway rather than exerting a broad impact on the global signaling pathway.

Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers

Anticancer role of flubendazole: Effects and molecular mechanisms (Review)

Flubendazole, FDA-approved Anthelmintic, Elicits Valid Antitumor Effects by Targeting P53 and Promoting Ferroptosis in Castration-Resistant Prostate Cancer.

Flubendazole suppresses VEGF‐induced angiogenesis in HUVECs and exerts antitumor effects in PC‐3 cells

Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer

Flurbiprofen Suppresses the Inflammation, Proliferation, Invasion and Migration of Colorectal Cancer Cells Via COX2.

Flubendazole Elicits Antitumor Effects by Inhibiting STAT3 and Activating Autophagy in Non-small Cell Lung Cancer

Drug Repurposing Flubendazole to Suppress Tumorigenicity Via PCSK9-dependent Inhibition and Potentiate Lenvatinib Therapy for Hepatocellular Carcinoma

Repurposing flubendazole for glioblastoma ferroptosis by affecting xCT and TFRC proteins

Oral Fenbendazole for Cancer Therapy in Humans and Animals

Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways

From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies

Discovery of anticancer function of Febrifugine: Inhibition of cell proliferation, induction of apoptosis and suppression steroid synthesis in bladder cancer cells

Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma

Flurbiprofen axetil is involved in basal‐like breast cancer metastasis via suppressing the MEK/ERK signaling pathway

Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database

Repositioning of Antiparasitic Drugs for Tumor Treatment

Revisiting Activity of Some Nocodazole Analogues as a Potential Anticancer Drugs Using Molecular Docking and DFT Calculations

Anti-tumor activity of beauvericin: focus on intracellular signaling pathways

Molecular mechanisms of bufadienolides and their novel strategies for cancer treatment

Recent advances in flavonoid compounds for the treatment of prostate cancer